(Q34263959)

English

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

1 August 2017

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial (English)

1 reference

Europe PubMed Central

1 August 2017

0 references

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Vincent A Miller

1

1 reference

Europe PubMed Central

1 August 2017

Vera Hirsh

2

1 reference

Europe PubMed Central

1 August 2017

Jacques Cadranel

3

1 reference

Europe PubMed Central

1 August 2017

Yuh-Min Chen

4

1 reference

Europe PubMed Central

1 August 2017

Keunchil Park

5

1 reference

Europe PubMed Central

1 August 2017

Sang-We Kim

6

1 reference

Europe PubMed Central

1 August 2017

Caicun Zhou

7

1 reference

Europe PubMed Central

1 August 2017

Wu-Chou Su

8

1 reference

Europe PubMed Central

1 August 2017

Mengzhao Wang

9

1 reference

Europe PubMed Central

1 August 2017

Yan Sun

10

1 reference

Europe PubMed Central

1 August 2017

Dae Seog Heo

11

1 reference

Europe PubMed Central

1 August 2017

Lucio Crino

12

1 reference

Europe PubMed Central

1 August 2017

Eng-Huat Tan

13

1 reference

Europe PubMed Central

1 August 2017

Tsu-Yi Chao

14

1 reference

Europe PubMed Central

1 August 2017

Mehdi Shahidi

15

1 reference

Europe PubMed Central

1 August 2017

Xiuyu Julie Cong

16

1 reference

Europe PubMed Central

1 August 2017

Robert M Lorence

17

1 reference

Europe PubMed Central

1 August 2017

James Chih-Hsin Yang

18

1 reference

Europe PubMed Central

1 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

26 March 2012

1 reference

Europe PubMed Central

1 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

1 August 2017

13

1 reference

Europe PubMed Central

1 August 2017

528-538

1 reference

Europe PubMed Central

1 August 2017

5

1 reference

Europe PubMed Central

1 August 2017

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Endpoints for assessing drug activity in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970087-6

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70087-6

1 reference

Europe PubMed Central

1 August 2017

1 reference

Europe PubMed Central

1 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34263959&oldid=1949811525"